Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) continues its trajectory in pioneering a new class of Synthetic Antiinfectives, spotlighting its recent achievement. The company announced that Scientia Clinical Research has successfully finalized cohort dosing for both male and female subjects. This is part of the crucial Phase I/II UTI/Urosepsis clinical trial, focusing on evaluating the performance of RECCE 327 (R327) at enhanced infusion rates.

A significant milestone was achieved when R327 demonstrated a safe and well-tolerated profile with a quicker infusion rate of 30 minutes for a 3,000mg dose. The robust data will soon be reviewed by an Independent Safety Committee. The anticipation is high as the committee is expected to give the green light for further proceedings, given that recruitment is already in full swing.

Recce Pharmaceuticals CEO James Graham voiced his enthusiasm, stating, “R327’s administration at a swifter infusion rate of 3,000mg underscores its safety among both male and female subjects. This not only bolsters R327’s safety profile but also accentuates its potential as an effective treatment option. As a therapy for UTI/Urosepsis, R327 is set to address a significant health concern responsible for approximately 30% of all sepsis infections.”

For those closely following Recce Pharmaceuticals Ltd and its Synthetic Antiinfective endeavors, the forward momentum of R327 in the UTI/Urosepsis clinical trial space is undeniably a story to watch.

  Australia, James Graham, R327, Recce Pharmaceuticals, urosepsis